TP53 and cancer: More generally, reduced RP stoichiometry is a common theme in cancers, especially when p53 is inactive (Ajore et al., 2017), and is associated with poor patient outcomes (Guimaraes and Zavolan, 2016; Kulkarni et al., 2017).